α7 nicotinic acetylcholine receptors (nAChRs) are widely expressed in the central nervous system and regarded as potential therapeutic targets for neurodegenerative conditions, such as Alzheimer’s disease and schizophrenia. This evidence concerns the gene CHRNA7 and early-onset autosomal dominant Alzheimer disease.